News
Clinical Trials Arena on MSN21h
Exicure concludes subject enrolment in trial of GPC-100 for multiple myelomaExicure has concluded subject enrolment in its ongoing randomised Phase II trial on GPC-100 (burixafor) in conjunction with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback